Production (Stage)
BioCryst Pharmaceuticals, Inc.
BCRX
$10.59
$0.201.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.64% | 12.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.64% | 12.34% | |||
| Cost of Revenue | -24.71% | 25.42% | |||
| Gross Profit | 36.51% | 4.38% | |||
| SG&A Expenses | 2.48% | 23.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.63% | 24.36% | |||
| Operating Income | 570.87% | -158.61% | |||
| Income Before Tax | 102.92% | -93.28% | |||
| Income Tax Expenses | -9.70% | 37.20% | |||
| Earnings from Continuing Operations | 100.12% | -90.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 100.12% | -90.94% | |||
| EBIT | 570.87% | -158.61% | |||
| EBITDA | 986.07% | -130.40% | |||
| EPS Basic | 100.15% | -90.56% | |||
| Normalized Basic EPS | 102.94% | -92.86% | |||
| EPS Diluted | 100.08% | -90.56% | |||
| Normalized Diluted EPS | 102.81% | -92.86% | |||
| Average Basic Shares Outstanding | 0.72% | 0.23% | |||
| Average Diluted Shares Outstanding | 3.80% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||